Get startedLog in
    Picture of StemCyte International logo

    4178 — StemCyte International Cashflow Statement

    0.000.00%
    tw flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for StemCyte International, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M
    Source:PROSPECTUSPROSPECTUSAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinal
    Net Income/Starting Line-128-332-205-173
    Depreciation
    Amortisation
    Non-Cash Items13.817528.1-27.7
    Discontinued Operations
    Unusual Items
    Equity in Net Earnings/Losses
    Other Non-Cash Items
    Changes in Working Capital21.76.37-27.484.6
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-35.5-92.7-141-52.4
    Capital Expenditures-5.47-5.61-31.4-2.48
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-78.1-99.9-187-106
    Acquisition of Business
    Sale of Business
    Sale/Maturity of Investment
    Purchase of Investments
    Sale of Intangible Assets
    Other Investing Cash Flow
    Cash from Investing Activities-83.6-105-218-109
    Financing Cash Flow Items00.502-0.129-0.483
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-30.17871,174-10.1
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-99.6556919-246